DEF: REGENXBIO Sets May 29, 2026 Annual Meeting Agenda

REGENXBIO Inc. announced its 2026 Annual Meeting of Stockholders, scheduled for May 29, 2026, to elect directors, ratify auditor selection, and vote on executive compensation and stock option exchange proposals.

Summary

• REGENXBIO Inc. is holding its Annual Meeting of Stockholders on May 29, 2026, at its Rockville, Maryland offices.
• Key agenda items include the election of three Class II directors (Jean Bennett, M.D., Ph.D., A.N. Jerry Karabelas, Ph.D., and Daniel Tass) for three-year terms.
• Stockholders will vote on ratifying the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the year ending December 31, 2026.
• An advisory vote on executive compensation and proposals to approve stock option exchanges for both non-executive and executive employees are also on the agenda.
• The meeting will address any other business properly brought before it.
• Stockholders of record as of April 1, 2026, are entitled to vote.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral to slightly negative due to the significant clinical setbacks mentioned for RGX-121 and the reliance on stock option exchanges to address employee retention issues stemming from stock price performance.

Positives

• The company is holding its annual meeting to ensure shareholder engagement and governance.
• Director nominees possess a diverse range of relevant experience in life sciences, public company leadership, finance, and regulatory affairs.
• The company maintains strong corporate governance practices, including independent board committees and a lead independent director.
• The company has a commitment to sustainability and equal opportunity.
• The company is proposing stock option exchange programs to retain key employees and restore incentive value, which is designed to be value-neutral and reduce overhang.
• PricewaterhouseCoopers LLP has served as the independent auditor since 2015, indicating a stable auditor relationship.

Negatives

• The company experienced a clinical hold and a Complete Response Letter (CRL) from the FDA for the RGX-121 program for MPS II.
• The company's stock price has faced significant pressure, leading to a large number of 'underwater' stock options for employees.
• The proposed stock option exchanges, while intended to be value-neutral, involve complex exchange ratios and a reduction in the number of shares for new options, which could be perceived negatively by some shareholders.
• The company reported a net loss of $193,878,000 for 2025.

Risks

• The FDA's clinical hold and CRL for RGX-121 pose a significant risk to the development and potential commercialization of this program.
• The decline in stock price and the resulting underwater stock options present a retention risk for key employees, potentially impacting the company's ability to execute its strategic plan.
• Increased regulatory uncertainty and safety/efficacy data from peer companies in the AAV gene therapy sector create broader industry risks.
• The company faces competition for attracting and retaining experienced personnel in the biotechnology sector.

Future Outlook

The company's focus remains on advancing its gene therapy pipeline, particularly ABBV-RGX-314, RGX-202, and RGX-121, and strengthening partnerships. The proposed stock option exchanges aim to retain key personnel crucial for achieving future milestones and commercialization.

Management Comments

• Director nominees have the right mix of experience, qualifications and skills and represent a mix of diverse experience, background and thought to contribute to our strategy and to the Boards ability to perform its duties.
• PricewaterhouseCoopers LLP (PwC) is an independent accounting firm with the breadth of expertise and knowledge necessary to effectively audit our business.
• Executive compensation targets are determined based on an annual peer group review and annual analysis of all elements of executive compensation for each executive.
• The Employee Option Exchange is intended to restore the incentive value of existing equity for these employees, support retention and motivation in a competitive labor market, and strengthen the alignment of employee interests with long-term stockholder value.
• The Executive Employee Option Exchange is intended to restore the incentive value of existing equity for these employees, support retention and motivation in a competitive labor market, and strengthen the alignment of employee interests with long-term stockholder value.

Industry Context

StockSavvy.ai notes that REGENXBIO operates in the highly competitive and rapidly evolving gene therapy sector. The company's reliance on equity compensation for talent retention is a common strategy in biotech, especially when facing stock price volatility. The challenges with the RGX-121 program highlight the inherent risks and regulatory hurdles in developing novel gene therapies.

Comparison to Industry Standards

• The company's director compensation structure, including cash retainers and equity awards, appears to be in line with industry standards for publicly traded biotechnology companies of similar size and stage.
• The proposed stock option exchange programs are a recognized, albeit sometimes controversial, tool used by companies in the biotechnology sector to address underwater stock options and retain talent, especially during periods of market downturn.
• The company's peer group for executive compensation benchmarking is standard practice in the industry to ensure competitive pay packages.

Corporate Governance

Legal Proceedings

• The FDA placed the RGX-121 program on clinical hold in January 2026 due to a serious adverse event.
• The FDA issued a Complete Response Letter (CRL) for the RGX-121 BLA in February 2026.

Related Party Transactions

• No related party transactions exceeding $120,000 were disclosed for the years ended 2025 and 2024.

Stakeholder Impact

• Shareholders: Voting on director elections, auditor ratification, executive compensation, and stock option exchanges. The option exchanges aim to reduce overhang and improve retention, potentially benefiting long-term value.
• Employees: Eligible employees can participate in stock option exchanges to restore incentive value. Non-executive employees are proposed to exchange options for fewer shares with new vesting terms. Executive employees have a separate, similar proposal.
• Management: Will oversee the implementation of approved proposals and continue to manage clinical development and business strategy.

Next Steps

• Stockholders to vote on the proposals at the Annual Meeting on May 29, 2026.
• If approved, the company will proceed with the stock option exchange programs for non-executive and executive employees.
• The company will continue to address the FDA's clinical hold and CRL for the RGX-121 program.
• The company will continue to advance its ABBV-RGX-314, RGX-202, and RGX-121 programs.

Key Dates

Recommendation

The filing is a routine proxy statement for an annual meeting. While the company is advancing its pipeline, the significant clinical setback with RGX-121 (FDA clinical hold and CRL) introduces substantial risk. The proposed stock option exchanges, while aimed at retention, highlight the impact of stock price performance on employee morale and the company's ability to retain key talent. Without more concrete financial performance or positive clinical trial updates, a 'hold' recommendation is prudent, pending further developments.

Keywords

REGENXBIO, Proxy Statement, Annual Meeting, Stockholders, Directors, Executive Compensation, Stock Options, Gene Therapy, Biotechnology, FDA, PricewaterhouseCoopers